Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Concert Pharma (CNCE) Tops Q2 EPS by 30c
August 4, 2022 7:21 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q2 EPS of ($0.59), $0.30 better than the analyst estimate of ($0.89).
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More